Locoregional Outcomes in an Inner City Underserved Population of Triple-negative Breast Cancer Patients Receiving Induction Therapy with Platinum Salts and Docetaxel
Jean L. Wright(University of North Carolina at Chapel Hill), Judith Hurley(University of Miami), JP Leone(University of Miami), V. Gunaseelan(University of Miami), Cristiane Takita(University of Miami), Steven E. Rodgers(University of Miami), Isildinha M. Reis(University of Miami), Victor Guardiola(Ocean Medical Center), Mark D. Pegram(Stanford University)
International Journal of Radiation Oncology*Biology*Physics
October 5, 2009
Cited by 1
Related Papers
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
|The Lancet|2018|779
Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline
|Practical Radiation Oncology|2018|615
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
|Journal of Clinical Oncology|2019|590
Effectiveness of early orthodontic treatment with the twin-block appliance: A multicenter, randomized, controlled trial. Part 1: Dental and skeletal effects
|American Journal of Orthodontics and Dentofacial Orthopedics|2003|374